10-K: OrthoPediatrics Corp. Reports Fiscal Year 2024 Results, Highlights Strategic Growth and Acquisitions

OrthoPediatrics Corp. announces its financial results for the fiscal year ended December 31, 2024, showcasing revenue growth, strategic acquisitions, and a commitment to pediatric orthopedic care.

Summary

• OrthoPediatrics Corp. reported a revenue increase of 38% to $204.7 million for the year ended December 31, 2024, compared to $148.7 million in 2023.
• The company's trauma and deformity correction product line saw a 36% revenue increase, reaching $145.1 million in 2024.
• Scoliosis product revenue increased by 45% to $55.2 million, representing 27% of total revenue.
• Sports medicine/other product revenue increased by 11% to $4.4 million, accounting for 2% of total revenue.
• The company's gross margin was 73% for 2024, a slight decrease from 75% in 2023.
• Operating losses were $35.0 million for 2024, compared to $26.8 million in 2023.
• The company incurred a net loss of $37.8 million for 2024, compared to a net loss of $21.0 million in 2023.
• As of December 31, 2024, OrthoPediatrics had $473.2 million in total assets, $118.6 million in total liabilities, and $354.6 million in stockholders' equity.
• The company completed the acquisition of Boston Brace International, Inc. in January 2024, contributing to revenue growth.
• OrthoPediatrics replaced an $80 million credit agreement with MidCap Financial with a $100 million term loan and private placement arrangement with Braidwell LP which includes a $50 million term loan and $50 million of convertible notes.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While revenue growth and strategic acquisitions are positive, ongoing losses and increased operating expenses temper the overall outlook. The company's commitment to social impact and innovation adds a slightly positive note.

Positives

• Significant revenue growth driven by strategic acquisitions and strong performance in key product categories.
• Continued expansion of product portfolio and market reach.
• Commitment to social impact and philanthropic causes.
• Focus on innovation and surgeon training to advance pediatric orthopedics.
• The company has impacted the lives of over 1,140,000 children since inception, including those served by acquired companies.

Negatives

• Operating losses and net losses continue, with an accumulated deficit of $235.6 million as of December 31, 2024.
• Gross margin decreased slightly from 75% in 2023 to 73% in 2024.
• The company recorded an impairment charge of $1.8 million related to the ApiFix trademark asset.

Risks

• Inability to achieve or sustain profitability.
• Dependence on commercialization of existing products and development of new products.
• Intense competition in the orthopedic industry.
• Potential for product liability claims and recalls.
• Risks associated with international business operations and regulatory compliance.
• Potential impacts from healthcare policy changes and unfavorable economic conditions.
• The company is subject to certain federal, state and foreign fraud and abuse laws and health information privacy and security laws, which, if violated, could subject us to substantial penalties.

Future Outlook

The company expects to continue expanding its product offering and investing in its global sales organization to reach new customers. They also plan to launch at least one new surgical system and multiple product line extensions each year.

Management Comments

• The Company and its associates regularly participate in numerous philanthropic causes important to our local communities.
• We are committed to fostering an environment that is respectful, compassionate, and inclusive of everyone in our community, which is communicated in our diversity and inclusion policy.
• The Company and its Board of Directors understand the value of diversity.

Industry Context

The company operates in the competitive orthopedic industry, focusing exclusively on the pediatric market, which they believe has been largely neglected by larger players. They aim to address unmet clinical needs with innovative products and technologies.

Comparison to Industry Standards

• The company competes with larger orthopedic companies like Johnson & Johnson MedTech, Medtronic plc, and Smith & Nephew plc.
• OrthoPediatrics believes it has the broadest pediatric product offering compared to its competitors.
• The company's strategy includes focusing on high-volume children's hospitals, similar to how larger companies target major adult orthopedic centers.
• The company's commitment to clinical education and research mirrors efforts by larger companies to build relationships with surgeons.

Legal Proceedings

• The company is involved in a lawsuit filed by IMED Surgical, LLC, claiming ownership of certain patented software.
• The company is involved in a lawsuit arising from the alleged wrongful death of a patient following a tracheal and laryngeal resection procedure at Boston Childrens Hospital.

Related Party Transactions

• The company uses Structure Medical, LLC, an affiliate of Squadron, as one of its suppliers.

Stakeholder Impact

• Shareholders: Dilution may occur from the conversion of convertible notes.
• Employees: Restructuring initiatives may impact employee morale and retention.
• Customers: Continued product innovation and support aim to improve patient outcomes.
• Suppliers: The company relies on a limited number of third-party suppliers.
• Creditors: The company has entered into a new term loan and private placement arrangement with Braidwell LP.

Next Steps

• Continue focus on high-volume children's hospitals.
• Provide a broad product portfolio of implant systems, specialty bracing products, and enabling technologies uniquely designed to treat children.
• Deploy instrument sets and provide unparalleled sales support.
• Expand addressable market through aggressive investment in research and development and select acquisition opportunities.
• Train the next generation of pediatric orthopedic surgeons.

Key Dates